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ABSTRACT 
The use of dietary supplements has increased dramatically, making drug interactions with 
those supplements a major concern. Because dietary supplements are not subject to the same 
regulations as prescription drugs, we hypothesize that the content of their active ingredients 
may vary among manufacturers, potentially causing a large variation in therapeutic outcome. 
The current study aimed to test this hypothesis on commonly used cranberry dietary supple-
ments. Activity of human CYP3A4 enzyme was used as a parameter to determine the effect of 
cranberry supplement from nine manufacturers. The content of a cranberry product, equiva-
lent to one capsule, was extracted with methanol. Aliquots of the extract were tested for their 
ability to inhibit the metabolism of the human CYP3A4 substrate quinine, using an in vitro 
liver microsomal technique. Human liver microsomes and quinine were incubated with or 
without (i.e. as control) cranberry extract. Formation of quinine’s metabolite 3-hydroxy-
quinine, generated by the CYP3A4-mediated reaction was measured by a HPLC method. Of 
nine cranberry products tested, eight products had little or no effect but only one brand (Na-
ture’s Herbs 600 mg) caused very strong inhibition (67.2 %) of CYP3A4. The reason for this 
inhibition is unknown. The effect of cranberry was varied and ranged from 4.4 % activation 
by Ride Aid 800 mg to 67.2 % inhibition by Nature’s Herbs 600 mg. Lack of effect on human 
CYP3A4 activity suggests that use of cranberry dietary supplement is unlikely to cause signif-
icant interactions with drugs metabolized by CYP3A4.  
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INTRODUCTION 
It has been recognized for many years 
that the medicinal use of herbs plays an 
important role in nearly every culture, in-
cluding Asia, Africa, Europe and the Unit-
ed States of America. Recent surveys indi-
cate that one of three Americans use die-
tary supplements daily (Kelly et al., 2005; 
Tindle et al., 2005). It is remarkable that 
the rate of herbal usage is much higher in 
cancer patients (Carmady and Smith, 2011; 
Carpenter et al., 2009; Pierce et al., 2002). 
Many of these supplements are herbal in 
nature (Wargovich, 2001). Herbal supple-
ments are normally taken for two main 
reasons. In the first situation they are used 
to improve symptoms of illness. For exam-
ple, the widespread use of St. John’s wort 
for relief of depression, use of Ginkgo bi-
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loba for improvement in cognition and the 
use of Echinacea for relief of cold symp-
toms (Wargovich, 2001). In the second 
case, herbal supplements are used particu-
larly with the hopes of preventing disease 
or reducing the risk for certain diseases. 
For example, the utilization of green tea, 
grape seed extract and other flavonoid-rich 
botanicals to take advantage of the natural 
antioxidants in these products (Nassiri-Asl 
and Hosseinzadeh, 2009; Wargovich, 
2001). The use of garlic and its supplement 
preparation is another example, as it has 
been demonstrated to prevent and reduce 
risk to cancer (Zhou et al., 2011). 
Cranberry (Vaccinium macrocarpon) is 
among the top 10 herbs sold in the United 
States (Blumenthal, 2003). Cranberry juice 
concentrate has been formulated into cap-
sules and sold as dietary supplements. 
There are many products of cranberry die-
tary supplements available in various US 
markets. Consumption of cranberry juice is 
useful for the treatment and prevention of 
urinary tract infections (Guay, 2009; Jep-
son and Craig, 2007). Cranberry juice ex-
tracts have also been suggested to possess 
anticancer effects (Bomser et al., 1996; 
Kresty et al., 2011; Neto, 2011). Cranber-
ries contain significant levels of vitamin C, 
total phenols, catechins and anthocyanins 
with associated antioxidant activity (How-
ell, 2007; Krenn et al., 2007). Though 
cranberry juice and cranberry dietary sup-
plements have become very popular, its 
potential interaction with drugs has not 
been well documented. It has been shown 
that cranberry juice did not alter the dispo-
sition of cyclosporine, suggesting it does 
not interact with other drugs metabolized 
by CYP3A4 (Grenier et al., 2006). There 
has been an increasing number of case re-
ports of life-threatening interactions be-
tween cranberry and warfarin (Abdul et al., 
2008; Haber et al., 2012).  
Cytochrome P450 (CYP) is a family of 
isoenzymes, mainly found in the liver and 
gut wall. There are more than 50 human 
CYP isoforms, but CYP1A2, CYP2C9, 
CYP2C19, CYP2D6 and CYP3A4 en-
zymes metabolize 90 % of clinically used 
drugs (Guengerich, 1999; Lynch and Price, 
2007). CYP plays an important role in de-
toxification and the elimination of many 
drugs and other xenobiotics including car-
cinogens. Human CYP3A4 is the most 
important human CYP isozyme because it 
is involved in the metabolism of approxi-
mately 50 % marketed drugs and some 
environmental toxicants (Guengerich, 
1999; Zhou, 2008). Human CYP3A4 is 
expressed in the gut, colon, small intestine, 
breast and prostate. However, its expres-
sion is most abundant in the liver which 
accounts for 30 % of the total CYP protein 
content (Guengerich, 1999; Lown et al., 
1997). Activity of CYP3A4 can be inhibit-
ed or induced by drugs, herbs, pesticides 
and carcinogens (Jiang et al., 2012; Zhou, 
2008). Also human CYP3A4 metabolizes 
most prescription drugs. This makes drug 
interactions with CYP3A4 extremely im-
portant (Guengerich 1999; Shi and Klotz, 
2012). Natural ingredients in grapefruit 
juice, primarily furanocoumarin deriva-
tives, have the capacity to inhibit intestinal 
CYP3A4 enzyme, accounting for a number 
of clinically important drug interactions 
(Bailey et al., 1998; Greenblatt et al., 2001; 
Ho et al., 2000). Therefore the use of die-
tary supplements such as cranberry is of 
concern with regard to herbal drug interac-
tions. 
Since dietary supplements including 
cranberry dietary supplements, are not reg-
ulated by the same FDA regulations as 
prescription drugs and over the counter 
medications, they normally lack quality 
control and the regulatory oversight of 
therapeutic products (Frankos et al., 2010; 
Sanzini et al., 2011). Thus, we hypothesize 
that the content of active ingredients in 
cranberry dietary supplements may vary 
among different manufacturers. This varia-
tion in the active ingredients may result in 
variation in therapeutic outcomes and ex-
tent of herbal drug interactions. This hy-
pothesis is based on the following previous 
findings. First, with regard to antioxidant 
activity of grape polyphenols, there was a 
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correlation between the antioxidant activity 
and the content of polyphenols in grape 
seed extracts (Zhao et al., 1999). Second, it 
has been testified with a few herbal sup-
plements, including ephedra, ginseng and 
St. John’s wort, that the content of active 
ingredients varied largely between brands 
and in some instances the content variation 
was also found between batches of the 
same herbal products (Draves and Walker, 
2003; Gurley et al., 2000; Harkey et al., 
2001). Therefore, this study was conducted 
to test this hypothesis on commonly used 
cranberry dietary supplements. Activity of 
human liver CYP3A4 was employed as a 
parameter to determine the effect of cran-
berry dietary supplements purchased from 
various manufacturers. 
 
MATERIALS AND METHODS 
Chemicals and dietary supplements 
All chemicals and reagents used were 
of analytical grade. Quinine hydrochloride 
dehydrate, NADPH and sodium dodecyl 
sulfate were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). 3-Hy-
droxyquinine was a gift from Dr. Peter 
Winstanley, Department of Pharmacology 
and Therapeutics, University of Liverpool, 
UK. Pooled human liver microsomes were 
purchased from In Vitro Technologies 
(Baltimore, MD, USA) and were kept 
at -80 °C until required. The CYP content 
of the microsomes was 0.29 nmol of 
CYP/mg of protein. Nine different brands 
of cranberry supplements were randomly 
purchased from local health product stores 
in California, USA, during the year 2009. 
Details of manufacturers, content of each 
capsule and indications are listed in Table 
1. All experiments were carried out well 
before the expiration dates of the cranberry 
dietary supplement products investigated.  
 
Preparation of cranberry supplement 
methanolic extract 
The content of cranberry dietary sup-
plement studied was measured by weigh-
ing the actual content in each capsule. This 
was done with six replicates (n = 6 cap-
sules). The contents from these six cap-
sules were combined. The mean (average) 
content of the capsule was determined. 
Content of each cranberry supplement 
equivalent to the average content in one 
capsule was extracted with methanol using 
procedures as previously described (Wan-
wimolruk and Prachayasittikul, 2012).  
 
 
Table 1: Product information of the cranberry supplements used in this study 
 
Brand Name Manufacturer mg/capsule Indication* 
GNC General Nutrition Corp. 500 mg Supports a healthy urinary tract 
Kroeger Kroeger Herb Products 
Co Inc. 
200 mg No claim 
Natural Balance 
(Cran Balance) 
Natural Balance 500 mg Provides nutritive support for urinary 
tract health 
Natural Factors 
(Cran Rich) 
Natural Factors, Cana-
da 
500 mg Supports urinary tract health 
Nature’s An-
swer 
Nature’s Answer, Inc. 800 mg As a traditional treatment for support-
ing healthy urinary tract function 
Nature’s Herbs Nature’s Herbs 600 mg Nutritionally supports healthy urinary 
tract function 
Nature’s Way Nature’s Way Prod-
ucts, Inc. 
400 mg Supports urinary tract health 
Pharm Assure Pharm Assure, Inc. 500 mg Helps maintain a healthy urinary tract 
Rite Aid Rite Aid Corp. 850 mg Supports urinary tract 
* These statements have not been evaluated by the Food and Drug Administration (FDA). This product is 
not intended to diagnose, treat, cure, or prevent disease. 
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CYP3A4 assay procedure 
Aliquots (5 µL) of the cranberry meth-
anolic extracts were tested for their ability 
to inhibit the metabolism of a CYP3A4 
marker substrate using an in vitro liver 
microsomal technique. All experiments 
were performed in four replicates. Quinine 
was used as marker substrate for human 
CYP3A4 (Zhang et al., 1997). Human liver 
microsomes (0.5 mg/mL) were incubated 
with quinine (100 µM) in the presence or 
absence (i.e. control) of cranberry meth-
anolic extract with 1 mM NADPH in 
phosphate buffer (0.067 M, pH 7.4) at a 
final volume of 0.5 mL. Each incubation 
was performed at 37 °C in shaking water 
bath for 30 min. The reaction was stopped 
by the addition of cold methanol solution 
(1 mL). The samples were vortexed briefly 
and centrifuged at 2500 g for 10 min. The 
resultant supernatant (30 µL) was injected 
onto the HPLC column. The formation of 
quinine’s metabolite (3-hydroxyquinine) 
was assayed by a reversed-phase HPLC 
method (Wanwimolruk et al., 1996). The 
detection limit of this assay was 0.1 µM 
(0.034 µg/mL). 
 
Statistical analysis 
Results are expressed as mean ± stand-
ard deviation (S.D.). Data were analyzed 
by one way ANOVA, followed by multiple 
comparisons using a Tukey’s test for post 
hoc comparison. Statistical analysis was 
assessed by SPSS statistical software (Ver-
sion 18.0, SPSS Inc., Chicago, IL, USA). 
For all tests differences were considered to 
be significant when p < 0.05. 
 
RESULTS AND DISCUSSION 
Preliminary study has demonstrated 
that the cranberry dietary supplement 
products of interest did not have any com-
pounds which can interfere with the HPLC 
assay of the CYP3A4 metabolite (3-
hydroxyquinine). This was confirmed by 
the results obtained from incubation of 
each cranberry supplement extract with 
human liver microsomes under the same 
experimental conditions used, without 
CYP3A4 substrate quinine. After incuba-
tion, none of the cranberry supplement 
extracts had peaks that interfere with 3-
hydroxyquinine in the HPLC assay.  
Figure 1 shows the effect of cranberry 
dietary supplement extract on the activity 
of human CYP3A4. The results showed 
that the majority of cranberry products 
tested had no or very little inhibitory effect 
on the activity of CYP3A4. Three of the 
cranberry product extracts, i.e. Kroeger 
200 mg, Pharm Assure 500 mg and Rite 
Aid 850 mg, caused minor activation of 
CYP3A4 activity. However, the extent of 
CYP3A4 activation by these three products 
was very small, ranging from 4.2 % for 
Pharm Assure 500 mg to 6.1 % for 
Kroeger 200 mg.  
 
Figure 1: Effect of cranberry supplement ex-
tracts on human CYP3A4 activity. Results were 
expressed as mean values and S.D. bars, ob-
tained from 4 measurements. 
 
The actual activity of CYP3A4 in the 
presence of all cranberry extract was not 
significantly different (p > 0.05) from that 
observed in the controls. One exception 
was the Nature’s Herbs 600 mg brand 
which caused a strong CYP3A4 inhibition 
of 67.2 ± 2.5 %. The actual CYP-3A4 ac-
tivity in the presence of the Nature’s Herbs 
600 mg brand was significantly less than 
(7.1 ± 0.7 pmol/min/mg vs 21.5 ± 1.4 
pmol/min/mg, p < 0.05) that observed in 
the controls. The reason for the inhibition 
of CYP3A4 enzyme caused by the Na-
ture’s Herbs product is unknown. The pos-
sible interference of the cranberry supple-
ment extract on HPLC analysis of 3-
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hydroxyquinine was excluded. This is be-
cause our preliminary results have demon-
strated that after the human microsomal 
mixture was incubated with the cranberry 
supplement extract without the CYP3A4 
substrate (quinine), no interfering peak was 
found. The difference could not be due to 
difference in content of cranberry dietary 
supplement products as there was no sig-
nificant correlation (r = 0.012, p > 0.5) 
between % inhibition of CYP3A4 caused 
by different brands and cranberry contents 
claimed in the capsule. This is also sup-
ported by the fact that the Nature’s Answer 
(800 mg) brand product contained higher 
cranberry content than that of Nature’s 
Herbs brand (600 mg), but it caused virtu-
ally no inhibitory effect (0 ± 2.5 % inhibi-
tion) on the activity of CYP3A4 (Figure 1). 
The marked inhibitory effect produced by 
the Nature’s Herbs brand (600 mg) may be 
caused by other phytochemical compounds 
in this cranberry product, which are not 
present in other cranberry brands. There is 
also a possibility of contamination during 
manufacturing processes. A product may 
also contain, as contaminants, parts of oth-
er herbs not mentioned on the label, which 
may not accurately reflect the herbal con-
tent of the product (Sanzini et al., 2011). If 
these are the cases, it points to the existing 
problem of quality control that is one of 
the main issues in the use of dietary sup-
plements (Frankos et al., 2010; Sanzini et 
al., 2011). 
The present study has shown that most 
of the cranberry dietary supplements tested 
had no significant effect on human 
CYP3A4 activity. Our in vitro finding sup-
ports previous observations which were 
reported by other investigators. For exam-
ple, a clinical study has shown that drink-
ing a glass of cranberry juice did not ap-
pear to alter the pharmacokinetics of cy-
closporine, suggesting it does not interact 
with other drugs metabolized by CYP3A4 
(Grenier et al., 2006). Similarly, a separate 
clinical study reported that cranberry juice 
had no effect on the pharmacokinetics of 
the CYP3A4 substrate midazolam (Lilja et 
al., 2007). In contrast, an in vitro study 
found that component(s) in cranberry juice 
caused a mechanism-based inhibition dur-
ing CYP3A-mediated oxidation of nifedi-
pine both in human liver and rat intestinal 
microsomes (Uesawa and Mohri, 2006). 
The authors suggested that a component or 
components present in cranberry juice in-
hibit human CYP3A-mediated metabolism 
of nifedipine. Inhibition of another human 
CYP3A4 drug, midazolam by commercial 
fruit juices, including cranberry juice, 
grapefruit juice, pomegranate, black rasp-
berry, black mulberry and wild grape juice 
during preincubation with NADPH, was 
also reported (Kim et al., 2006). A recent 
in vitro study had led to isolation of three 
triterpenes (maslinic acid, corosolic acid, 
and ursolic acid) from cranberry (Kim et 
al., 2011). These triterpenes were shown to 
be strong inhibitors of enteric human 
CYP3A4, with inhibitory potencies being 
within the range of those reported for 
CYP3A4 inhibitory components in grape-
fruit juice (Kim et al., 2011). Contradiction 
of results found from these studies could 
be related to the fact that some studies 
were conducted in vivo (healthy volun-
teers) whereas others were performed in 
vitro. It may also be accounted for by dif-
ferences in experimental conditions such as 
concentrations of cranberry juice or ex-
tracts used in those in vitro experiments.  
In summary, the current study has 
demonstrated that cranberry dietary sup-
plements with different brands caused no 
significant inhibitory effect on human 
CYP3A4. Lack of inhibitory effect on hu-
man CYP3A4 activity implies that use of 
cranberry dietary supplement is unlikely to 
cause significant interactions with drugs 
metabolized by CYP3A4 (e.g., felodipine, 
nifedipine, midazolam, cyclosporine, 
atorvastatin and saquinavir, etc.). Never-
theless, without good quality control im-
plemented for manufacturing dietary sup-
plements, there may be an inconsistency of 
products. This may cause variation in phy-
tochemical compounds which can generate 
unexpected herbal drug interactions. 
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